WO2020017585A1 - 外用製剤 - Google Patents
外用製剤 Download PDFInfo
- Publication number
- WO2020017585A1 WO2020017585A1 PCT/JP2019/028251 JP2019028251W WO2020017585A1 WO 2020017585 A1 WO2020017585 A1 WO 2020017585A1 JP 2019028251 W JP2019028251 W JP 2019028251W WO 2020017585 A1 WO2020017585 A1 WO 2020017585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- pain
- compound
- composition according
- external
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention relates to a therapeutic and / or prophylactic agent for pain, more specifically, N 2 - ⁇ [1-ethyl-6- (4-methylphenoxy) -1H-benzimidazol-2-yl] methyl ⁇ -L-alanine
- the present invention relates to an external preparation containing amide as an active ingredient for treating and / or preventing peripheral neuropathic pain.
- Pain in the peripheral nerves is a significant symptom in many medical conditions, and to a large extent, can also have a significant effect on human QOL and can interfere with a variety of general human functions.
- the mechanism of pain sensing in the peripheral nerves is known to be painful by transmitting pain signals from the peripheral sensory nerves to the brain via the spinal cord. It has been found that channels are involved and that the sodium channel at each point of action is a different type of channel. In this case, sodium channels in the brain are Nav1.1 to Nav1.4 and Nav1.6, and sodium channels in the peripheral sensory nerves are Nav1.7 to Nav1.9. Another sodium channel is Nav1.5 in the heart.
- lidocaine As an external pain agent that acts on sodium channels, a lidocaine formulation is commercially available, and its high transdermal absorption and its effective therapeutic effect on pain have already been demonstrated, but it also has cardiotoxic side effects. Because of their reports, medical practice places severe restrictions on their use. That is, lidocaine is considered to not only effectively act on sodium channels in peripheral nerves, but also act on Nav1.5, which affects the heart. In general, it is not always easy to develop a therapeutic agent for pain using sodium channels in terms of side effects, and it is particularly important to obtain channel selectivity. Was.
- Patent Document 1 The research team of the present inventors has clarified that a bicyclic heterocyclic compound already having a predetermined structure has a pain effect, and that the action inhibits peripheral sensory nerve-specific Na channels (SNS).
- Patent Document 1 the confirmation of the action using the Na channel as an index in Patent Document 1 is limited to evaluation by an in vitro test, and pharmacokinetic studies such as transdermal absorption are not performed at all.
- pharmacokinetic studies such as transdermal absorption are not performed at all.
- it is necessary to examine the pharmacokinetic effects taking into account the efficiency of transdermal absorption and metabolism, as well as the applicability to formulations suitable for topical administration and formulation stability. Needed.
- studying the selectivity of sodium channels was also an essential issue. However, even if they are examined, it is necessary to select a practical compound from among many compounds examined in Patent Document 1 and to examine the reduction of side effects in consideration of the selectivity of sodium channel. It was not easy to do.
- An object of the present invention is to provide an external preparation for treating peripheral neuropathic pain.
- N 2 - ⁇ [1-ethyl-6- (4-methylphenoxy) -1H-benzimidazole-2- [Ill] methyl ⁇ -L-alaninamide is suitable for use as an external preparation in terms of percutaneous absorption, and the preparation has good storage stability and is an existing pain remedy.
- the present inventors have found that they have the same level of pain effect as lidocaine ointment preparations, and surprisingly show excellent safety far superior to lidocaine in terms of reduction of side effects on the cardiovascular system, thereby completing the present invention.
- the present invention is as follows.
- An active ingredient comprising N 2 - ⁇ [1-ethyl-6- (4-methylphenoxy) -1H-benzimidazol-2-yl] methyl ⁇ -L-alaninamide or a pharmaceutically acceptable salt thereof.
- the topical pharmaceutical composition of the present invention has excellent percutaneous absorbability, excellent storage stability, and shows an excellent effect similar to that of an existing topical lidocaine drug by topical administration with respect to pain, and has an effect on the heart. Because of its small amount, it is expected to be an easy-to-use pain treatment drug with a greater degree of discrepancy between pain action and side effects on the heart than lidocaine topical drug.
- the pharmaceutically acceptable salt in the present invention includes a salt of an acid which forms a salt with a basic functional group in the above-mentioned compound of the present invention, specifically, hydrochloride, hydrobromic acid Salts, sulfates, nitrates, acetates, trifluoroacetates, methanesulfonates, toluenesulfonates, citrates and the like.
- pain is intended to mean pain felt in peripheral nerves and involves peripheral nerves such as C fibers and A ⁇ fibers; spontaneous pains such as numbness, burning sensation, dull pain, stinging, and electric shock; It can be used as a therapeutic or prophylactic agent for neuropathic pain with hyperalgesia or allodynia to mechanical or cold stimuli; nociceptive pain; inflammatory pain; small diameter neuropathy; .
- neuropathic pain examples include, for example, diabetic neuropathy, postherpetic neuralgia, neuropathy due to chemotherapy, cancer pain, human immunodeficiency syndrome virus infectious sensory neuropathy, trigeminal neuralgia, complex regional pain syndrome, Reflex sympathetic dystrophy, lumbar postoperative neuralgia, phantom limb pain, spinal cord injury pain, prolonged postoperative pain, inflammatory demyelinating polyradiculopathy, alcoholic neuropathy, strangulated peripheral neuropathy, doctor Neuropathy, idiopathic sensory neuropathy, neuropathy due to malnutrition, post-irradiation neuropathy, radiculopathy, toxic peripheral neuropathy, traumatic peripheral neuropathy, brachial plexus withdrawal injury, tongue neuralgia, Examples include autoimmune neuropathy, chronic cauda equina disorder, limb pain, lip extremity pain and the like.
- Nociceptive pain or inflammatory pain includes low back pain, back pain, abdominal pain, rheumatoid arthritis, pain due to osteoarthritis, myalgia, acute postoperative pain, bone fracture pain, burn pain and the like.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can also be used as a therapeutic or preventive agent for dysuria.
- the urination disorder include frequent urination, bladder pain due to prostatic hypertrophy, and the like.
- the compound of the present invention has the purpose of enhancing its action, for example, celecoxib, ibuprofen, loxoprofen, acetaminophen, non-steroidal anti-inflammatory drugs such as diclofenac, steroidal anti-inflammatory drugs such as dexamethasone and prednisolone, tramadol, morphine, oxycodone And other opioid analgesics.
- non-steroidal anti-inflammatory drugs such as diclofenac
- steroidal anti-inflammatory drugs such as dexamethasone and prednisolone, tramadol, morphine, oxycodone And other opioid analgesics.
- antiepileptic drugs such as pregabalin and carbamazepine, aldose reductase inhibitors such as epalrestat, prostaglandin derivative preparations such as limaprost alfadex, antidepressants such as amitriptyline and duloxetine, anticonvulsants, anxiolytics, dopamine receptors It can be used in combination with a drug such as a body agonist, a Parkinson's disease drug, a hormone preparation, a migraine drug, an adrenergic ⁇ receptor antagonist, a dementia drug, or a mood disorder drug.
- a drug such as a body agonist, a Parkinson's disease drug, a hormone preparation, a migraine drug, an adrenergic ⁇ receptor antagonist, a dementia drug, or a mood disorder drug.
- an antiepileptic drug such as pregabalin and carbamazepine
- an antidepressant drug such as amitriptyline and duloxetine
- a narcotic drug such as morphine, oxycodone and tramadol
- Analgesics, anti-inflammatory drugs such as acetaminophen, diclofenac, dexamethasone, aldose reductase inhibitors such as epalrestat, and prostaglandin derivatives such as limaprost @ alphadex.
- the timing of administration of the compound of the present invention and the concomitant drug is not limited, and they may be administered to the subject at the same time, or may be administered at appropriate intervals. Further, the compound of the present invention and a concomitant drug may be used as a combination, or may be administered as a separate preparation from the compound of the present invention, or may be administered by another administration route. The dose of the concomitant drug can be appropriately determined based on the clinically used dose.
- the compounding ratio of the compound of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination and the like.
- the concomitant drug may be used in an amount of 0.01 to 1000 parts by weight based on 1 part by weight of the compound of the present invention.
- the "external pharmaceutical composition” is a composition for allowing a drug component to directly act on an affected area of pain by administering transdermally or transmucosally, and its formulation form is a coating, a patch, or a spray.
- Agent aerosol
- plasters, ointments, creams, gels, liniments, lotions and the like are used as coatings, and cataplasms, tapes, patches, plasters and the like as patches.
- a coating agent, a patch, or a spray (aerosol) having a low water content is used.
- the composition of the present invention may be a liquid or semi-solid composition as a coating agent, a semi-solid or solid composition as a patch, or a mist or powder as a spray (aerosol).
- the composition is in the form of a foam or a paste. From the viewpoint of storage stability of the compound of the present invention, the lower the water content, the better.
- the content of water in the composition is not particularly limited, but is preferably 5% or less, more preferably 3% or less, and more preferably 1% or less based on the total mass of the composition. More preferably, it is 0.5% or less, further preferably 0.1% or less.
- substantially contains no water means a water content of not more than a level that does not greatly affect the storage stability of the compound of the present invention, and specifically, 5 to the total mass of the composition. %, Preferably 3% or less, more preferably 1% or less, further preferably 0.5% or less, further preferably 0.1% or less. preferable.
- the coating agent in the external pharmaceutical composition of the present invention specifically includes liquid or semi-solid compositions such as plasters, ointments, creams, gels, liniments, and lotions. Ointments with a low pH are preferred. Ointments include oral ointments and eye ointments.
- the type and properties of the solvent or the base contained in the composition are not particularly limited, and may be hydrophobic such as hydrophilic or oily, and further, a plurality of different solvents and bases may be used. May be appropriately mixed and emulsified before use.
- solvents and bases include, as oily components, petrolatum (white, yellow), gelled hydrocarbons (Plastibase (registered trademark)), paraffins (liquid paraffin), lanolin, hydrolanolin, lanolin Alcohol, polyethylene glycol, silicone, waxes (bee wax), vegetable oil, lard, squalane, simple ointment, etc., and aqueous components such as water, glycerin, propylene glycol, 1,3-butylene glycol, ethanol, isopropanol, etc.
- Oily components petrolatum (white, yellow), gelled hydrocarbons (Plastibase (registered trademark)), paraffins (liquid paraffin), lanolin, hydrolanolin, lanolin Alcohol, polyethylene glycol, silicone, waxes (bee wax), vegetable oil, lard, squalane, simple ointment, etc.
- aqueous components such as water, glycerin, propylene glycol, 1,3-butylene glyco
- the content of the compound of the present invention or a pharmaceutically acceptable salt thereof in the coating composition is not particularly limited, but is preferably 0.01 to 10% by weight, more preferably 0.1 to 6% by weight. Is more preferable, and the content is particularly preferably 0.3 to 3% by weight.
- composition of the coating composition of the present invention may contain, in addition to the above-mentioned solvents and bases, additives used in the field of pharmaceuticals, cosmetics and the like according to the dosage form of pharmaceutical preparations, the administration method and the like.
- additives include, for example, gelling agents, alcohols, polyhydric alcohols, fats and oils, waxes, hydrocarbons, fatty acids, fatty acid esters, emulsifiers, solubilizers, pH adjusters, antioxidants, softeners, Examples include a thickener, a humectant, a preservative, a stabilizer, a flavoring agent, and a transdermal absorption promoter.
- examples of the alcohol include benzyl alcohol, cetyl alcohol, lauryl alcohol, decanol, oleyl alcohol, octyl dodecanol, octyl alcohol and the like.
- examples of the polyhydric alcohol include ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerin, and 1,3-butylene glycol.
- examples of the fats and oils include sesame oil, soybean oil, castor oil, olive oil and the like.
- examples of the waxes include polyoxyethylene sorbite beeswax, microcrystalline wax, wax mixed with cetanol and polyethylene glycol monostearate, and the like.
- hydrocarbon examples include squalane, squalene, liquid paraffin, and the like.
- Fatty acids include, for example, oleic acid, behenic acid, myristic acid, stearic acid, isostearic acid and the like.
- fatty acid ester examples include isopropyl myristate, diisopropyl adipate, diethyl sebacate, octyldodecyl myristate, and the like.
- emulsifier include polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid ester, glycerin fatty acid ester, and alkyl glyceryl ether.
- solubilizer examples include isopropanol, oleic acid, ethyl oleate, polysorbate 80, anhydrous ethanol, nicotinamide and the like.
- pH adjuster examples include hydrochloric acid, sodium hydroxide, meglumine, phosphoric acid, succinic acid, maleic acid, triisopropanolamine, monoethanolamine and the like.
- antioxidants examples include 2-mercaptobenzimidazole, L-ascorbic acid palmitate, 3 (2) -t-butyl-4-methylphenol, propyl gallate, ⁇ -tocophenol, 1,3-butylene Glycol, benzotriazole, L-ascorbic acid, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, sodium bisulfite, sodium edetate and the like.
- softening agent examples include liquid paraffin, purified lanolin, squalane, squalene, olive oil, sesame oil, camellia oil, persic oil and peanut oil, isopropyl myristate, isopropyl oleate, diisopropyl adipate, triglyceride of medium-chain fatty acids, and the like.
- preservative examples include alkyl parahydroxybenzoates, benzoic acid, sodium benzoate and the like.
- thickener examples include celluloses such as methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, nitrocellulose, cationized cellulose, xanthan gum, guar gum, cationized guar gum, starch, cationized starch, sodium hyaluronate, Examples include alginic acid, carrageenan, carboxyvinyl polymer, polyacrylic acid, polyvinyl alcohol, polyethylene glycol, polypropylene glycol and the like.
- Examples of flavoring agents include l-menthol, dl-menthol, peppermint oil, eucalyptus oil, lavender oil, rose oil, orange oil and the like.
- Examples of the transdermal absorption enhancer include acetic acid, lactic acid, citric acid, malic acid, butyl acetate, ethyl lactate, cetyl lactate, propylene carbonate, crotamiton, N-methyl-2-pyrrolidone, triacetin, medium-chain triglyceride, Examples include chain fatty acid diglyceride, medium chain fatty acid monoglyceride, methyl isobutyl ketone, triethanolamine, lecithin, polybutylene and the like.
- composition of the spray (aerosol) of the present invention includes a solvent for dissolving the drug, an alcohol which improves the absorption effect from the transdermal or transmucosal membrane when the drug is jetted, and also has a dissolving aid function.
- Formulation components such as a thickener for maintaining the particle size at the time of spraying and a propellant for jetting a liquid containing a drug are included.
- propellant examples include LPG (liquefied petroleum gas containing propane, i-butane and n-butane as main components), n-pentane, i-pentane, dimethyl ether, 1,1,1,2-tetra
- a liquefied gas such as fluoroethane or a chlorofluorocarbon gas instead of 1,1-difluoroethane can be used, and these can be used alone or in combination of two or more.
- a compressed gas such as air, nitrogen, oxygen, carbon dioxide, and nitric oxide can be mixed with the liquefied gas.
- the thickener include methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, nitrocellulose, celluloses such as cationized cellulose, xanthan gum, guar gum, cationized guar gum, starch, cationized starch, hyaluronic acid Examples thereof include sodium, alginic acid, carrageenan, carboxyvinyl polymer, polyacrylic acid, polyvinyl alcohol, polyethylene glycol, and polypropylene glycol, and these can be used alone or in combination of two or more.
- monohydric lower alcohols and polyhydric alcohols are preferable.
- Representative examples of the monohydric lower alcohol include alcohols having 2 to 4 carbon atoms such as ethanol, denatured ethanol, n-propanol, i-propanol, n-butanol and i-butanol.
- Representative examples of polyhydric alcohols include ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerin, and 1,3-butylene glycol.
- the patch of the present invention is a patch comprising a support and an adhesive layer laminated on at least one surface of the support, wherein the adhesive layer contains the compound of the present invention or a pharmaceutically acceptable compound thereof. And a formulation component such as a softener, a tackifier, and an absorption enhancer.
- the content of the compound or a pharmaceutically acceptable salt thereof contained in the pressure-sensitive adhesive layer as the patch of the present invention is not particularly limited, but is 30 to 80 based on the total mass of the pressure-sensitive adhesive layer of the patch of the present invention. %, Preferably 40-70% by weight.
- a softening agent it is preferable to further contain at least one selected from the group consisting of liquid paraffin, squalane, isopropyl myristate, olive oil, camellia oil, persic oil and peanut oil.
- the amount is preferably from 1 to 70% by mass based on the total mass of the pressure-sensitive adhesive layer.
- the tackifier is not particularly limited, but preferred examples thereof include alicyclic saturated hydrocarbon resin (petroleum resin), terpene resin, rosin resin, rosin ester resin, oil-soluble phenol resin and the like.
- the absorption enhancer is not particularly limited as long as it is a compound that has been shown to have an absorption promoting effect on the skin.
- Preferred examples thereof include fatty acids, aliphatic alcohols, fatty acid esters, fatty acid ethers, and aromatic organic compounds. Examples include acids, aromatic alcohols, aromatic organic acid esters, and aromatic organic acid ethers.
- the support is not particularly limited as long as it is a support generally used for a patch.
- the material include polyesters such as polyethylene terephthalate (PET), polybutylene terephthalate and polyethylene naphthalate; polyolefins such as polyethylene and polypropylene; nylon A polycarbonate; a metal such as aluminum is preferably used.
- PET polyethylene terephthalate
- polybutylene terephthalate and polyethylene naphthalate polyolefins such as polyethylene and polypropylene
- nylon A polycarbonate a metal such as aluminum is preferably used.
- the support is preferably used in the form of a film, a cloth, a foil, a porous sheet, or the like, or a form in which these are laminated.
- the surface of the pressure-sensitive adhesive layer opposite to the support may be covered with a release liner.
- a release liner is a release film for covering and protecting the pressure-sensitive adhesive layer, and may be any release liner generally used for a patch, and is not particularly limited.
- examples of such a release liner include resin films such as polyesters (polyethylene terephthalate, polyethylene naphthalate, polybutylene terephthalate, etc.), polyolefins (polyethylene, polypropylene, etc.), paper, cellulose derivatives, and the like. It is preferable that the surface in contact with is coated with silicone, Teflon (registered trademark) or the like and then subjected to a release treatment. In particular, a silicone-treated polyethylene terephthalate film is suitably used.
- the thickness of the pressure-sensitive adhesive layer in the patch of the present invention is not particularly limited, but is generally preferably 30 to 500 ⁇ m, more preferably 40 to 300 ⁇ m, and further preferably 50 to 200 ⁇ m. preferable.
- N 2 - ⁇ [1-ethyl-6- (4-methylphenoxy) -1H-benzimidazol-2-yl] methyl ⁇ -L-alanineamide of the compound of the present invention is referred to as “compound A ".
- Example 1 An ointment preparation was prepared in Examples 1 to 6 and Comparative Example 1 below, a patch was prepared in Examples 7 and 8, and a gel preparation was prepared in Example 9.
- Example 1 Compound A was mixed and dissolved with 1% by mass of 7% by mass of oleic acid, and 92% by mass of white petrolatum was added and kneaded and kneaded so as to obtain an ointment preparation.
- Example 2 Compound A was mixed with 1% by mass of 7% by mass of oleic acid, mixed and dissolved, and 91% by mass of white petrolatum and 1% by mass of water for injection were added, and the mixture was kneaded and kneaded so that an ointment was prepared. did.
- Example 3 Compound A was mixed with 1% by mass of 7% by mass of oleic acid, mixed and dissolved, 89% by mass of white petrolatum and 3% by mass of water for injection were added, and the mixture was uniformly mixed to prepare an ointment preparation. .
- Example 4 Oleic acid (7% by mass) was added to Compound A (1% by mass), mixed and dissolved, white petrolatum (87% by mass) and water for injection (5% by mass) were added, and the mixture was uniformly mixed to prepare an ointment preparation.
- Example 5 Compound A was mixed with 1% by mass of 7% by mass of oleic acid and dissolved therein, and 92% by mass of gelled hydrocarbon was added thereto.
- Example 6 Compound A was mixed and dissolved with 6% by mass of 44% by mass of oleic acid, and 50% by mass of gelled hydrocarbon was added thereto.
- Embodiment 7 Production example of adhesive patch (production example of rubber-based adhesive) 0.5 g of polyisobutylene (Oppanol N-100: BASF Co., Ltd.), 0.24 g of liquid paraffin (Hicor M-352; Kaneda Co., Ltd.), polybutene (Nisseki Polybuden HV-300F; JXTG Energy Co., Ltd.) 0 0.3 g and 0.6 g of an alicyclic saturated hydrocarbon resin (Alcon P-100; Arakawa Chemical Industries, Ltd.) were dissolved in 6 mL of tetrahydrofuran to obtain an adhesive layer.
- polyisobutylene Oppanol N-100: BASF Co., Ltd.
- liquid paraffin Hicor M-352; Kaneda Co., Ltd.
- polybutene Neki Polybuden HV-300F; JXTG Energy Co., Ltd.
- Alcon P-100 alicyclic saturated hydrocarbon resin
- polyethylene terephthalate and / or ethylene vinyl acetate copolymer laminate film (Scotchpak # 9732) manufactured by 3M Healthcare Co., Ltd. was used as the support.
- release liner a binder sheet 64S-018B manufactured by Fujimori Kogyo Co., Ltd. was used.
- Embodiment 8 FIG. Production example of adhesive patch (production example of acrylic adhesive) 0.854 g of an acrylic adhesive (DURO-TAK 387-2287, manufactured by Henkel, solid content: 51% by mass), 0.3 mL of ethyl acetate, and oleic acid so that the content in the adhesive layer becomes 10% Mixed. Compound A dissolved in 0.4 mL of methanol was added to this mixture so that the content in the adhesive layer became 3%, and the mixture was sufficiently stirred to obtain a mixture. The obtained mixture was spread on a support so that the thickness after drying was about 60 ⁇ m, and dried at room temperature for one day. Thereafter, a release liner was attached to produce a tape preparation.
- an acrylic adhesive DURO-TAK 387-2287, manufactured by Henkel, solid content: 51% by mass
- Compound A dissolved in 0.4 mL of methanol was added to this mixture so that the content in the adhesive layer became 3%, and the mixture was sufficiently stirred to obtain a mixture
- Embodiment 9 FIG. Preparation Example of Gel Preparation Compound A was mixed and dissolved by adding 7% by mass of oleic acid to 1% by mass. In this solution, 6.4% by mass of hydrogenated soybean phospholipid (Resinol S-10; Nikko Chemicals Co., Ltd.) and 27.6% by mass of medium-chain fatty acid triglyceride (Triester F-810; Nikko Chemicals Co., Ltd.) Glycerin triisooctanoate (Trifat S-308; Nikko Chemicals Co., Ltd.) 4.6% by mass, octyldodecyl myristate (ODM-100; Nikko Chemicals Co., Ltd.) 12.9% by mass, microcrystalline wax (purified micro 5.5% by mass of crystallin wax; Nikko Guatemala Co., Ltd .; 3.0% by mass of dextrin palmitate (Dextrin palmitate N; Nikko Chemicals Co., Ltd.); monostearyl g
- Comparative Example 1 Ointment preparation was manufactured by adding white vaseline (93% by mass) to oleic acid (7% by mass), mixing and mixing uniformly.
- Test Example 1 Storage stability test of ointment preparation An accelerated stability test was performed on the ointment preparations obtained from Examples 1 to 4 and Comparative Example 1. About 5 g of each ointment preparation immediately after production was filled in a polypropylene ointment jar for a capacity of 6 mL, and stored at 60 ° C. The drug content after storage was determined by weighing the ointment preparation from the ointment jar, adding 2 mL of tetrahydrofuran and stirring, adding 2 mL of a 50% methanol solution and stirring, and measuring the aqueous layer after centrifugation by HPLC.
- the following table shows the residual drug amount (%) after storage.
- Test example 2 Measurement of Analgesic Effect in Fifth Lumbar Ligation Model
- the inhibitory effect of compound A and lidocaine on neuropathic pain was confirmed by evaluating the analgesic effect in the fifth lumbar nerve ligation (SNL) model.
- the SNL model was created by partially modifying the method of Kim and Chung (Pain 50, 355-363, 1992). That is, a male 5-week-old Wistar rat was exposed to pentobarbital and isoflurane anesthesia to expose the fifth lumbar nerve on one side, and the fifth lumbar nerve was ligated with a silk suture to prepare an SNL model. The von Frey test was used to evaluate the analgesic effect.
- Response thresholds were measured the day before and two days before the test compound was evaluated, and the average value was defined as the response threshold before administration of the test compound.
- One day after the grouping the test compound was administered.
- the ointment preparation of Example 1 was administered to the compound A administration group, lidocaine ointment 5% (USP) sold by Taro Pharmaceuticals USA, Inc. in the United States was administered to the lidocaine administration group, and the control example was administered to the solvent administration group.
- USP lidocaine ointment 5%
- the administration of the test compound was performed by applying about 10 mg of each preparation to a medical adhesive film, and applying the preparation to the surgical footpad of an SNL rat under anesthesia by inhalation of isoflurane. One hour after application, the film was peeled off, and one hour later, the reaction threshold after administration of the test compound was evaluated. After the evaluation, blood was immediately collected from the jugular vein, and the plasma concentration of the test compound was measured.
- the analgesic effect of the test compound is (Reaction threshold after administration of test compound)-(Reaction threshold before administration of test compound) Is expressed as an extension width of the reaction threshold value ⁇ standard error (g) by the following formula.
- the extended range of the reaction threshold in the solvent administration group, the compound A administration group, and the lidocaine administration group was 0.0 ⁇ 0.37 g, 2.2 ⁇ 0.56 g, and 4.1 ⁇ 0.62 g, respectively.
- the extended range of the response threshold of the compound A administration group and the lidocaine administration group was statistically significantly increased as compared with the solvent administration group, respectively. No significant difference was found.
- the plasma concentrations of compound A and lidocaine were 25.2 ng / mL and 132.6 ng / mL, respectively.
- Test Example 3 Cardiovascular Safety Pharmacology Test The effect of Compound A or lidocaine on the cardiovascular system was confirmed by the effect on ECG (Electrocardiogram) parameters in guinea pigs under anesthesia. Evaluation of the electrocardiogram in guinea pigs was performed under anesthesia by intraperitoneal administration of a urethane and ⁇ -chloralose mixture. The anesthetized guinea pig was held in a supine position, the right jugular vein was exposed, and a cannula was placed.
- a solvent for dissolving the test compound a solvent prepared using 20% polyethylene glycol 400, 10% dimethylformamide, 10% ethanol, and 0.6% lactic acid was used.
- the solvent increased the PR time by 15.2%, the QRS time by 8.4% and the QTc time by 30% 30 minutes after administration.
- Lidocaine increased PR time by 35.1%, QRS time by 44.5%, and QTc time by 15.8% 30 minutes after administration.
- the change rates of various parameters of lidocaine were statistically significantly different from those after the administration of the solvent.
- the highest plasma concentration of lidocaine at the time of 15 mg / kg administration was 3.57 ⁇ g / mL.
- Compound A prolonged PR time by 22.3%, QRS time by 10.3% and QTc time by 9.0% 30 minutes after administration.
- the change rates of the various parameters of Compound A were not statistically significantly different from the various parameters after the solvent administration.
- the maximum plasma concentration of Compound A at the time of administration of 30 mg / kg was 16.9 ⁇ g / mL.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
末梢神経での疼痛を感じるメカニズムは、末梢の感覚神経から脊髄を経由して脳へと痛みのシグナルが伝達することで痛いと感じることが知られており、その経路における各作用点においてはナトリウムチャネルが関与しており、またその各作用点におけるナトリウムチャネルはそれぞれ異なるタイプのチャネルであることがわかっている。
この場合、脳におけるナトリウムチャネルはNav1.1~Nav1.4、Nav1.6であり、末梢感覚神経におけるナトリウムチャネルはNav1.7~Nav1.9ある。また別のナトリウムチャネルとして心臓においてはNav1.5が存在する。
しかしながら、特許文献1でのNaチャネルを指標とした作用の確認はin vitro試験による評価にとどまっており、経皮吸収性など薬物動態的な検討は一切行っておらず、末梢部位で局所投与による適用を実際実現するためには、経皮吸収の効率や代謝を考慮した薬物動態的影響を検討する必要があり、また局所投与に適した製剤への適用性や製剤の安定性なども検討する必要があった。更に、上記のリドカインでの副作用の懸念を考慮すれば、ナトリウムチャネルの選択性の検討も必須課題であった。しかしながら、それらを検討するとしても、特許文献1の中で検討された多くの化合物の中から実用可能なものを選び出した上で、ナトリウムチャネルの選択性を考慮した上での副作用低減の検討を行うことは容易なことではなかった。
〔項1〕N2-{[1-エチル-6-(4-メチルフェノキシ)-1H-ベンゾイミダゾール-2-イル]メチル}-L-アラニンアミドまたはその医薬的に許容される塩を有効成分として含有する外用医薬組成物。
本発明において組成物に含まれる溶媒あるいは基剤の種類・性質等は特に限定されず、親水性であっても油性等の疎水性であってもよく、さらには異なる複数種の溶媒・基剤を適宜混合・乳化等して用いてもよい。こうした溶媒・基剤としては、具体的には例えば、油性成分としてはワセリン(白色、黄色)、ゲル化炭化水素(プラスチベース(登録商標))、パラフィン類(流動パラフィン)、ラノリン、加水ラノリン、ラノリンアルコール、ポリエチレングリコール、シリコン、ロウ類(ミツロウ)、植物油、豚脂、スクワラン、単軟膏などが挙げられ、水性成分として水、グリセリン、プロピレングリコール、1,3-ブチレングリコール、エタノール、イソプロパノールなどが挙げられる。本発明における溶媒・基剤としては油性のものが好ましい。
なお、以下の実施例において、本発明化合物のN2-{[1-エチル-6-(4-メチルフェノキシ)-1H-ベンゾイミダゾール-2-イル]メチル}-L-アラニンアミドは、「化合物A」と略す。
実施例1
化合物Aを1質量%にオレイン酸7質量%を添加して混合溶解し、白色ワセリン92質量%を添加して、均一になるように混和練合して軟膏製剤を製造した。
化合物Aを1質量%にオレイン酸7質量%を添加して混合溶解し、白色ワセリン91質量%、注射用水1質量%を添加して、均一になるように混和練合して軟膏製剤を製造した。
化合物Aを1質量%にオレイン酸7質量%を添加して混合溶解し、白色ワセリン89質量%、注射用水3質量%を添加して、均一になるように混和連合して軟膏製剤を製造した。
化合物A1質量%にオレイン酸7質量%を添加して混合溶解し、白色ワセリン87質量%、注射用水5質量%を添加して、均一になるように混和連合して軟膏製剤を製造した。
化合物A1質量%にオレイン酸7質量%を添加して混合溶解し、白色ワセリン82質量%、注射用水10質量%を添加して、均一になるように混和連合して軟膏製剤を製造した。
化合物Aを1質量%にオレイン酸7質量%を添加して混合溶解し、ゲル化炭化水素92質量%を添加して、均一になるように混和連合して軟膏製剤を製造した。
化合物Aを6質量%にオレイン酸44質量%を添加して混合溶解し、ゲル化炭化水素50質量%を添加して、均一になるように混和連合して軟膏製剤を製造した。
ポリイソブチレン(Oppanol N-100:BASF(株))0.5g、流動パラフィン(ハイコールM-352;カネダ(株))0.24g、ポリブデン(日石ポリブデンHV-300F;JXTGエネルギー(株))0.3g、脂環族飽和炭化水素樹脂(アルコン P-100;荒川化学工業(株))0.6gをテトラヒドロフラン6mLに溶解し、粘着剤層を得た。
化合物A0.02gをオレイン酸0.14gに添加して、溶解を確認後にミリスチン酸イソプロピル0.2gを添加し、先に調製した粘着剤層を加えて十分に撹拌して混合液を得た。得られた混合液を乾燥後の粘着剤層の厚さが約60μmとなるように支持体の上に延展し、室温で1日乾燥した。その後、剥離ライナーを貼り合わせてテープ製剤を製造した。この製剤中の化合物A含有量は1質量%である。
アクリル系粘着剤(DURO-TAK 387-2287、ヘンケル社製、固形分51質量%)0.854g、酢酸エチル0.3mL、および粘着剤層中の含有率が10%となるようにオレイン酸を混合した。この混合液に、粘着剤層中の含有量が3%になるように、メタノール0.4mLに溶解した化合物Aを添加し、十分に撹拌して混合液を得た。得られた混合液を、乾燥後の厚さが約60μmとなるように支持体の上に延展し、室温で1日乾燥した。その後剥離ライナーを貼り合わせてテープ製剤を製造した。
化合物Aを1質量%にオレイン酸7質量%を添加して混合溶解した。この溶解液に、水素添加大豆リン脂質(レシノールS-10;日光ケミカルズ(株))6.4質量%、中鎖脂肪酸トリグリセリド(トリエスターF-810;日光ケミカルズ(株))27.6質量%、トリイソオクタン酸グリセリン(Trifat S-308;日光ケミカルズ(株))4.6質量%、ミリスチン酸オクチルドデシル(ODM-100;日光ケミカルズ(株))12.9質量%、マイクロクリスタリンワックス(精製マイクロクリスタリンワックス;日興リカ(株))5.5質量%、パルミチン酸デキストリン(デキストリンパルミテートN;日光ケミカルズ(株))3.0質量%、モノステアリルグリセリルエーテル(バチルアルコールEX;日光ケミカルズ(株))2.0質量%、白色ワセリン25.0質量%、流動パラフィン8.0質量%を添加し、常温で均一分散した後、90℃に加温して撹拌し溶解した。その後、容器に充填して冷却し、ゲル製剤を得た。
オレイン酸7質量%に白色ワセリン93質量%を添加して、均一になるように混和連合して軟膏製剤を製造した。
実施例1~4および比較例1から得られた軟膏製剤について加速安定性試験を実施した。容量6mL用のポリプロピレン製の軟膏壺に製造直後の各軟膏製剤約5gを充填して、60℃条件下で保存した。保存後の薬物含量は、軟膏壺から軟膏製剤を量り取り、テトラヒドロフランを2mL加えて撹拌し、さらに50%メタノール溶液を2mL加えて撹拌し、遠心分離後の水層をHPLC法にて測定した。
(HPLC条件)
カラム:Gemini/NX-C18 3μm(4.6φ×100mm)
移動相A:10mMリン酸緩衝液(pH7.4)
移動相B:アセトニトリル
カラム温度:30℃
流速:2.0mL/分
検出器:紫外吸光光度計(測定波長:220nm)
移動相の送液:移動相A及び移動相Bの混合比を次のように変えて濃度勾配制御する。
化合物Aおよびリドカインの神経障害性疼痛の抑制効果は、第5腰神経結紮(SNL)モデルにおける鎮痛作用の評価により確認した。
SNLモデルの作成は、KimとChungの方法(Pain 50, 355-363, 1992)を一部改変して行った。すなわち、雄性5週齢Wistarラットをペントバルビタールおよびイソフルラン吸入による麻酔下にて片側の第5腰神経を露出させ、絹製の縫合糸で第5腰神経を結紮してSNLモデルを作成した。
鎮痛作用の評価方法は、von Frey testを採用した。すなわち、動物の手術側の後肢足蹠を毛髪(von Frey hair)でつつき、Chaplanらの方法(Journal of Neuroscience Methods 53, 55-63, 1994)に則った数式を用いることで、機械刺激に対する反応閾値(50% paw withdrawal thresholds)を算出した。
SNLモデル作成後7日目以降においては、動物の手術側の後肢の反応閾値は顕著に低下していることが予備検討により確認できたため、試験化合物の鎮痛作用は、SNL手術後7日目から10日目の何れかの日に評価した。試験化合物を評価する前日および前々日に反応閾値を測定し、平均した値を試験化合物投与前の反応閾値とした。
試験化合物投与前の反応閾値を平均した値の差が群間で小さくなるよう、および群内のばらつきが小さくなるよう、動物を3群(n=9)に分けた。群分け1日後、試験化合物の投与を行った。化合物A投与群には実施例1の軟膏製剤を、リドカイン投与群には米国でTaro Pharmaceuticals U.S.A., Inc.から販売されているリドカイン軟膏5%(米国薬局方)を、溶媒投与群には対照例1の軟膏製剤を使用した。試験化合物の投与は、医療用粘着フィルムに各種製剤約10mgを塗布し、イソフルラン吸入による麻酔下にてSNLラットの手術側足蹠に貼付することで行った。貼付1時間後にフィルムを剥離し、その1時間後に試験化合物投与後の反応閾値を評価した。評価後、速やかに頸静脈より採血を行い、試験化合物の血漿中濃度を測定した。
試験化合物の鎮痛作用の効力は、
(試験化合物投与後の反応閾値)-(試験化合物投与前の反応閾値)
の計算式によって反応閾値の延長幅±標準誤差(g)として表す。
溶媒投与群、化合物A投与群およびリドカイン投与群の反応閾値の延長幅は、それぞれ0.0±0.37g、2.2±0.56gおよび4.1±0.62gであった。化合物A投与群およびリドカイン投与群の反応閾値の延長幅は、溶媒投与群に比べそれぞれ統計学的有意に増加したが、化合物A投与群とリドカイン投与群の反応閾値の延長幅の間に統計学的有意な差は認められなかった。なお、化合物Aおよびリドカインの血漿中濃度は、それぞれ25.2ng/mLおよび132.6ng/mLであった。
以上の結果から、実施例1の軟膏製剤により化合物Aは経皮的に吸収され、病態動物モデルであるSNLモデルラットにおいて、良好な鎮痛作用を示すことが確認された。また、その鎮痛作用はリドカインと同等であった。
化合物Aあるいはリドカインの心臓血管系への作用は、麻酔下モルモットにおけるECG(Electrocardiogram)パラメータへの影響により確認した。モルモットにおける心電図の評価は、ウレタンおよびα-クロラロース混合液の腹腔内投与による麻酔下にて実施した。麻酔下のモルモットを仰臥位に保定し、右頸静脈を露出させてカニューレを留置した。試験化合物を溶解させる溶媒は20%のポリエチレングリコール400、10%のジメチルホルムアミド、10%のエタノール、0.6%の乳酸で調製された溶媒を使用した。溶媒で30mg/kgの投与量で溶解させた化合物A、溶媒で15mg/kgの投与量で溶解させたリドカイン、あるいは溶媒を、カニューレを介して一定速度で30分間持続静脈投与した。リドカインの心電図への作用の効力は、PR時間については、
{(投与後30分後のPR時間)-(投与前のPR時間)}/(投与前のPR時間)×100
の計算式によって変化率(%)として表す。QRS時間、QTc時間についても同様の計算式によって変化率(%)として表す。
投与開始から10分、20分、30分の時点で左頸静脈から採血を行い、化合物Aあるいはリドカインの血漿中濃度を測定した。
溶媒は投与30分後において、PR時間を15.2%、QRS時間を8.4%、QTc時間を6.0%延長させた。
リドカインは投与30分後において、PR時間を35.1%、QRS時間を44.5%、QTc時間を15.8%延長させた。リドカインの各種パラメータの変化率は溶媒投与後の各種パラメータと統計学的有意な差が認められた。15mg/kg投与時のリドカインの最高血漿中濃度は3.57μg/mLであった。
化合物Aは投与30分後において、PR時間を22.3%、QRS時間を10.3%、QTc時間を9.0%延長させた。化合物Aの各種パラメータの変化率は溶媒投与後の各種パラメータと統計学的有意な差は認められなかった。30mg/kg投与時の化合物Aの最高血漿中濃度は16.9μg/mLであった。
薬効モデルの結果と合わせると、化合物Aは鎮痛作用を示した時の血漿中濃度から約670倍高い血漿中濃度でも心臓血管系への作用は認められなかった。一方、リドカインは鎮痛作用を示した時の血漿中濃度から約27倍高い血漿中濃度でECGパラメータへの影響が認められた。よって、化合物Aはリドカインに比べ、より安全性の高い薬剤であることが判明した。
Claims (9)
- N2-{[1-エチル-6-(4-メチルフェノキシ)-1H-ベンゾイミダゾール-2-イル]メチル}-L-アラニンアミドまたはその医薬的に許容される塩を有効成分として含有する外用医薬組成物。
- ワセリン(白色、黄色)、ゲル化炭化水素、パラフィン類、ラノリン、加水ラノリン、ラノリンアルコール、ポリエチレングリコール、シリコン、ロウ類、植物油、豚脂、スクワラン、及び単軟膏からなる群より少なくとも1つを含む外用基剤を更に含む、請求項1の外用医薬組成物。
- 有効成分が0.01%(w/v)~10%(w/v)で含有する、請求項1または2の外用医薬組成物。
- 実質的に水を含有しない請求項1~3のいずれかの外用医薬組成物。
- 外用医薬組成物の製剤形が塗布剤、貼付剤またはスプレー剤(エアゾール剤)である、請求項1~4のいずれかの医薬組成物。
- 塗布剤が軟膏剤である、請求項5の外用医薬組成物。
- 疼痛の治療および/または予防用の請求項1~6のいずれかの外用医薬組成物。
- 疼痛が末梢性神経障害性疼痛である、請求項7の外用医薬組成物。
- 局所への外用投与において、有効成分の量が1回あたり0.1mg以上投与可能な、請求項1~8のいずれかの外用医薬組成物。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3105465A CA3105465A1 (en) | 2018-07-19 | 2019-07-18 | Medicinal preparation for external use |
EP19838338.2A EP3824887A4 (en) | 2018-07-19 | 2019-07-18 | MEDICINAL PREPARATION FOR EXTERNAL USE |
BR112021000183A BR112021000183A8 (pt) | 2018-07-19 | 2019-07-18 | Preparação medicinal para uso externo |
US17/260,123 US11925621B2 (en) | 2018-07-19 | 2019-07-18 | Medicinal preparation for external use |
EA202190317A EA202190317A1 (ru) | 2018-07-19 | 2019-07-18 | Лекарственный препарат для наружного применения |
KR1020217004351A KR20210034615A (ko) | 2018-07-19 | 2019-07-18 | 외용 제제 |
CN201980047992.4A CN112423749A (zh) | 2018-07-19 | 2019-07-18 | 用于外部使用的医学制剂 |
MX2021000714A MX2021000714A (es) | 2018-07-19 | 2019-07-18 | Preparacion medicinal para uso externo. |
JP2020531362A JP7391848B2 (ja) | 2018-07-19 | 2019-07-18 | 外用製剤 |
AU2019306705A AU2019306705A1 (en) | 2018-07-19 | 2019-07-18 | Medicinal preparation for external use |
IL280118A IL280118A (en) | 2018-07-19 | 2021-01-12 | Medical preparation for external use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018136147 | 2018-07-19 | ||
JP2018-136147 | 2018-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020017585A1 true WO2020017585A1 (ja) | 2020-01-23 |
Family
ID=69165160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/028251 WO2020017585A1 (ja) | 2018-07-19 | 2019-07-18 | 外用製剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11925621B2 (ja) |
EP (1) | EP3824887A4 (ja) |
JP (1) | JP7391848B2 (ja) |
KR (1) | KR20210034615A (ja) |
CN (1) | CN112423749A (ja) |
AU (1) | AU2019306705A1 (ja) |
BR (1) | BR112021000183A8 (ja) |
CA (1) | CA3105465A1 (ja) |
EA (1) | EA202190317A1 (ja) |
IL (1) | IL280118A (ja) |
MX (1) | MX2021000714A (ja) |
WO (1) | WO2020017585A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138717A1 (ja) | 2020-12-23 | 2022-06-30 | 住友ファーマ株式会社 | 経口固形製剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI436986B (zh) * | 2008-12-26 | 2014-05-11 | Dainippon Sumitomo Pharma Co | 新穎之2環性雜環化合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004510765A (ja) * | 2000-10-06 | 2004-04-08 | ニューロジェン・コーポレーション | Crf受容体調節物質としてのベンズイミダゾールおよびインドール誘導体類 |
JP2004514671A (ja) * | 2000-11-21 | 2004-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用 |
WO2010074193A1 (ja) | 2008-12-26 | 2010-07-01 | 大日本住友製薬株式会社 | 新規2環性複素環化合物 |
JP2012031152A (ja) * | 2010-06-28 | 2012-02-16 | Dainippon Sumitomo Pharma Co Ltd | 新規2環性複素環化合物からなる医薬 |
-
2019
- 2019-07-18 CA CA3105465A patent/CA3105465A1/en active Pending
- 2019-07-18 EP EP19838338.2A patent/EP3824887A4/en active Pending
- 2019-07-18 KR KR1020217004351A patent/KR20210034615A/ko unknown
- 2019-07-18 BR BR112021000183A patent/BR112021000183A8/pt unknown
- 2019-07-18 US US17/260,123 patent/US11925621B2/en active Active
- 2019-07-18 CN CN201980047992.4A patent/CN112423749A/zh active Pending
- 2019-07-18 EA EA202190317A patent/EA202190317A1/ru unknown
- 2019-07-18 AU AU2019306705A patent/AU2019306705A1/en active Pending
- 2019-07-18 MX MX2021000714A patent/MX2021000714A/es unknown
- 2019-07-18 JP JP2020531362A patent/JP7391848B2/ja active Active
- 2019-07-18 WO PCT/JP2019/028251 patent/WO2020017585A1/ja active Application Filing
-
2021
- 2021-01-12 IL IL280118A patent/IL280118A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004510765A (ja) * | 2000-10-06 | 2004-04-08 | ニューロジェン・コーポレーション | Crf受容体調節物質としてのベンズイミダゾールおよびインドール誘導体類 |
JP2004514671A (ja) * | 2000-11-21 | 2004-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用 |
WO2010074193A1 (ja) | 2008-12-26 | 2010-07-01 | 大日本住友製薬株式会社 | 新規2環性複素環化合物 |
JP2012031152A (ja) * | 2010-06-28 | 2012-02-16 | Dainippon Sumitomo Pharma Co Ltd | 新規2環性複素環化合物からなる医薬 |
Non-Patent Citations (3)
Title |
---|
CHAPLAN, JOURNAL OF NEUROSCIENCE METHODS, vol. 53, 1994, pages 55 - 63 |
KIMCHUNG, PAIN, vol. 50, 1992, pages 355 - 363 |
See also references of EP3824887A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138717A1 (ja) | 2020-12-23 | 2022-06-30 | 住友ファーマ株式会社 | 経口固形製剤 |
KR20230124655A (ko) | 2020-12-23 | 2023-08-25 | 스미토모 파마 가부시키가이샤 | 경구 고형 제제 |
Also Published As
Publication number | Publication date |
---|---|
BR112021000183A2 (pt) | 2021-06-01 |
MX2021000714A (es) | 2021-03-25 |
CA3105465A1 (en) | 2020-01-23 |
JPWO2020017585A1 (ja) | 2021-08-02 |
JP7391848B2 (ja) | 2023-12-05 |
US20210322385A1 (en) | 2021-10-21 |
EP3824887A4 (en) | 2022-04-13 |
IL280118A (en) | 2021-03-01 |
AU2019306705A1 (en) | 2021-01-28 |
CN112423749A (zh) | 2021-02-26 |
EP3824887A1 (en) | 2021-05-26 |
KR20210034615A (ko) | 2021-03-30 |
US11925621B2 (en) | 2024-03-12 |
EA202190317A1 (ru) | 2021-04-20 |
BR112021000183A8 (pt) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220105075A1 (en) | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents | |
US6239177B1 (en) | Tranilast-containing preparation for external application and method of producing the same | |
JP7145363B2 (ja) | 局所皮膜形成スプレー | |
TWI296531B (en) | Transdermal adhesive preparations for topical administration of fentanyl | |
WO1993009768A1 (en) | Fomentation containing ketorolac | |
KR20110017451A (ko) | 소염 진통 외용제 | |
AU2006220964A1 (en) | Topical gels compositions | |
US5795916A (en) | Composition of external preparation | |
JP2009013171A (ja) | メマンチン含有経皮吸収製剤 | |
JP7049258B2 (ja) | 水性貼付剤 | |
JP7391848B2 (ja) | 外用製剤 | |
KR20020012549A (ko) | 옥시부티닌 함유 경피흡수 제제 | |
JP4764337B2 (ja) | 消炎鎮痛貼付剤 | |
US9254325B2 (en) | Percutaneously absorbed preparation | |
US20050158371A1 (en) | Novel external agent | |
WO1992019271A1 (en) | Percutaneous administration and absorption promoter composition and external preparation for percutaneous administration | |
JP2024507266A (ja) | ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および/または処置におけるその使用 | |
JP2024507011A (ja) | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および/または処置におけるその使用 | |
BR122023027784A2 (pt) | Preparação medicinal para uso externo | |
EA045467B1 (ru) | Лекарственный препарат для наружного применения | |
JP6459148B2 (ja) | 経皮吸収型製剤 | |
WO2017057541A1 (ja) | 経皮吸収型製剤 | |
EP2298294A1 (en) | Oxybuprocaine-containing analgesic/antipruritic preparation for external application | |
JP2003160489A (ja) | オンダンセトロン経皮吸収用医薬組成物 | |
CA2244679C (en) | Tranilast-containing preparation for external application and method of producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19838338 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020531362 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3105465 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021000183 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019306705 Country of ref document: AU Date of ref document: 20190718 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20217004351 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019838338 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112021000183 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210106 |